U.S. Medical Supplies & Devices: Discontinuing Coverage

Research evidence excerpt

U.S. Medical Supplies & Devices: Discontinuing Coverage

Equity Research

29 May 2026

U.S. Medical Supplies & Devices

Discontinuing Coverage

Discontinuing CoverageWe are discontinuing coverage of the following stocks as a

result of the coverage analyst's departure from the firm.

POSITIVE

As a result of coverage analyst's departure from the Firm, we are discontinuing coverage of the Unchanged

following stocks. All previous ratings and forecasts should not be relied upon.

• Baxter International. Our final rating prior to departure was Overweight. Barclays Equity Research

GlobalEquityResearch@barclays.com

• Becton Dickinson. Our final rating prior to departure was Overweight.

• Boston Scientific Corp.. Our final rating prior to departure was Overweight.

• Medtronic PLC. Our final rating prior to departure was Overweight.

• Intuitive Surgical. Our final rating prior to departure was Overweight.

• Johnson & Johnson. Our final rating prior to departure was Equal Weight.

• Stryker Corp. Our final rating prior to departure was Overweight.

• Zimmer Biomet Holdings Inc. Our final rating prior to departure was Underweight.

• Abbott Laboratories. Our final rating prior to departure was Overweight.

• Edwards Lifesciences Corp.. Our final rating prior to departure was Overweight.

• Dexcom. Our final rating prior to departure was Underweight.

• Insulet. Our final rating prior to departure was Underweight.

• Tandem Diabetes. Our final rating prior to departure was Overweight.

• InMode. Our final rating prior to departure was Overweight.

• LivaNova. Our final rating prior to departure was Equal Weight.

• Alcon. Our final rating prior to departure was Equal Weight.

• Bausch + Lomb. Our final rating prior to departure was Equal Weight.

• Orchestra Biomed Holdings, Inc..